🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It's with great pleasure that I share with you our paper evaluating #cabozantinib with #nivolumab +/- #CBM588 in pts with advanced #kidneycancer, published today in Nature Medicine! 🙏Huge thanks 1st/foremost to patients & their families. Had tons of support from the amazing

Congrats Hedyeh , Dr. Pal and team. This is such a great achievement at such an early part of your life, Hedyeh. This is not only a testament to your hard work and relentless drive , but also the brilliance and nurturing environment that Dr. Pal offers to his team.

Another incredible accomplishment by Sumanta K. Pal, MD, FASCO and his extraordinary team of young trainees! Luis A. Meza Nazli Dizman Yale IM Traditional Residency Program Yale Internal Medicine Smilow Cancer Hospital

#KCRS24 Rapid Abstract: Renee Maria Saliby Dana-Farber studies intermediate endpoints for OS in metastatic RCC treated with ICIs. Time to Next Therapy (TTNT) is a strong predictor of survival. Abstract Book: bit.ly/KCRS24Abstracts Register: kcrs.kidneycan.org

#KCRS24 Session 7 featured our oral abstract presentations! Belzutifan v Everolimus Laurence Albiges Belzutifan Safety Profile Toni Choueiri, MD CDK4/6 Inhibition Bradley McGregor IL7 SNP, Adverse Events Eddy Saad Liquid Biopsy DNA Analysis Karl Semaan, MD, MSc Gut Microbiome & ICI Combos Nazli Dizman

So excited to see my colleague’s brilliant work. Your team leads the field in probiotics and microbiome in RCC. Looking forward to phase III.

🎤 Don't miss our latest roundtable featuring Laurence Albiges, Renee Maria Saliby, Tian Zhang, MD, MHS, and Shahla Bari MD discussing the risk stratification and management of metastatic #nccRCC. 👀 Watch Here: buff.ly/46jG3e9

Honored to have @BertrandRouty & @ArielleElkrief visiting City of Hope. Two superstars in the field of #microbiome who have inspired many of our efforts in #kidneycancer, including Regina Barragan-Carrillo’s study of #camucamu which is ongoing. Exciting to get a sneak peek at their data (not

Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T out on AACR Cancer Research Communications aacrjournals.org/cancerrescommu… Study explores the role of systemic innate

Thought provoking ……

He truly deserves it. Dan is an amazing mentor and a great person.

Thank you PCF Science and Nora for a wonderful visit and symposium with Mark C. Markowski at Instituto Nacional de Cancerología in Mexico City! Great idea exchanges and here’s to new collaborations! DCI Center for Prostate & Urologic Cancers

Kidney cancer Powerhouses Laurence Albiges and Sumanta K. Pal, MD, FASCO hosted by KidneyCAN for a special seminar on the latest research in Kidney cancer--Can't miss this one! LINK: kidneycan.org/latest-kidney-… Bryan Lewis Brian Rini, MD Brian Shuch, MD Tom Powles Gustave Roussy City of Hope

While this will certainly succeed , but not in the recent future. Current AI capabilities does not extend to knowing what is relevant for each diagnosis or treatment , therefore 1000 pages can indeed be converted to a table, but difficult to create a clinically useful summary

Dr. Jameel Muzaffar of Duke Cancer discusses advancements in head and neck cancer treatment highlighting personalized approaches and the role of HPV in oropharyngeal cancers. #MCIPrecisionOncology #CancerResearch

GU ASCO is such an amazing opportunity to meet colleagues, friends and mentors. Looking forward to working together. Nazli Dizman ASCO #GU25

Here is Trump saying yesterday verbatim "They rigged the election, and I became President" PLEASE SHARE THIS!!!! x.com/Cooperstreamin…

⚠️⚠️BREAKING: We need you to know about a critical development that directly impacts #kidneycancer research funding and the #KCRP. Speaker of the House, Mike Johnson, has scheduled a vote for this Tuesday, March 11th, on a continuing resolution extension bill that includes a

Few things have broken my spirit more since my diagnosis than watching the dismantling of funding for cancer research. Watching friends die from cancer, wishing there was more for them, while simultaneously watching the advancements to keep us alive threatened, cut, and our

#FacesOfKidneyCancer: "The only reason I’m here is because of research." When Chuck Stravin was diagnosed in 2015, zero federal dollars were allocated to #KidneyCancer research. Today, clinical trials, made possible by funding, are keeping him alive. #AcceleratingCures